JP2020532589A - Ｉｒｅ１阻害のための化合物および組成物 - Google Patents

Ｉｒｅ１阻害のための化合物および組成物 Download PDF

Info

Publication number
JP2020532589A
JP2020532589A JP2020534804A JP2020534804A JP2020532589A JP 2020532589 A JP2020532589 A JP 2020532589A JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020532589 A JP2020532589 A JP 2020532589A
Authority
JP
Japan
Prior art keywords
pyrazine
amino
naphthalene
imidazole
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020534804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532589A5 (enExample
Inventor
リチャード エム． キーネン
リチャード エム． キーネン
ブラッドリー ジェイ． バッケス
ブラッドリー ジェイ． バッケス
ダスティン ジェイ． マリー
ダスティン ジェイ． マリー
チャールズ レイノルズ
チャールズ レイノルズ
ベン ウィタカー
ベン ウィタカー
ジェイミー ナイト
ジェイミー ナイト
サットン　ジョン
ジョン サットン
ジョージ ハインド
ジョージ ハインド
フィローズ アール． パパ
フィローズ アール． パパ
スコット エー． オークス
スコット エー． オークス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020532589A publication Critical patent/JP2020532589A/ja
Publication of JP2020532589A5 publication Critical patent/JP2020532589A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020534804A 2017-09-01 2018-08-31 Ｉｒｅ１阻害のための化合物および組成物 Pending JP2020532589A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
US62/553,320 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (2)

Publication Number Publication Date
JP2020532589A true JP2020532589A (ja) 2020-11-12
JP2020532589A5 JP2020532589A5 (enExample) 2021-10-21

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534804A Pending JP2020532589A (ja) 2017-09-01 2018-08-31 Ｉｒｅ１阻害のための化合物および組成物

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521784A (ja) * 2019-02-27 2022-04-12 オプティキラ リミテッド ライアビリティ カンパニー Ｉｒｅ１阻害のためのピラゾロピリジン化合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
WO2020176761A1 (en) * 2019-02-27 2020-09-03 Optikira, LLC Imidazolopyrazine compounds for ire1 inhibition
EP4192462A4 (en) * 2020-08-07 2024-09-04 Optikira LLC PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM
US11884649B2 (en) * 2020-11-13 2024-01-30 The Regents Of The University Of California IRE1α inhibitors and uses thereof
EP4460492A1 (en) * 2022-01-07 2024-11-13 (INSERM) Institut National de la Santé et de la Recherche Médicale Compounds containing a hydroxyphenyl moiety and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
JP2015532287A (ja) * 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
EP3799870A1 (en) * 2010-04-05 2021-04-07 Fosun Orinove Pharmatech, Inc. Ire-1a inhibitors
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
AU2017228405A1 (en) * 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
JP2015532287A (ja) * 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS CHEMCAL BIOLOGY, vol. 11, JPN6022036766, 2016, pages 2195 - 2205, ISSN: 0004864683 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521784A (ja) * 2019-02-27 2022-04-12 オプティキラ リミテッド ライアビリティ カンパニー Ｉｒｅ１阻害のためのピラゾロピリジン化合物

Also Published As

Publication number Publication date
KR20200066301A (ko) 2020-06-09
WO2019046711A3 (en) 2020-04-02
RU2020112425A3 (enExample) 2022-03-31
ZA202001320B (en) 2023-10-25
BR112020004226A2 (pt) 2020-11-17
EP3675858A4 (en) 2021-03-17
IL272845B1 (en) 2023-08-01
WO2019046711A2 (en) 2019-03-07
US20200354367A1 (en) 2020-11-12
IL272845B2 (en) 2023-12-01
MX2020002322A (es) 2020-10-05
EP3675858B1 (en) 2023-04-26
IL272845A (en) 2020-04-30
SG11202001609RA (en) 2020-03-30
RU2020112425A (ru) 2021-10-04
CN111526877A (zh) 2020-08-11
CA3074139A1 (en) 2019-03-07
EP3675858A2 (en) 2020-07-08
AU2018326721B2 (en) 2022-12-01
AU2018326721A1 (en) 2020-03-12
CN111526877B (zh) 2023-08-25
US11649237B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
US10435389B2 (en) Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
JP2020532589A (ja) Ｉｒｅ１阻害のための化合物および組成物
JP5966014B2 (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
JP6663909B2 (ja) オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
US11434245B2 (en) WNT pathway modulators
US8729271B2 (en) Glycine transporter inhibiting substances
US8859768B2 (en) Heteroaryls and uses thereof
WO2007055418A1 (ja) アザ置換スピロ誘導体
US11541057B2 (en) Thienopyrimidinone NMDA receptor modulators and uses thereof
CN115697974A (zh) 基于咪唑3-氧化物衍生物的acss2抑制剂和其使用方法
JP2019511466A (ja) オレキシン受容体調節因子としてのハロ置換ピペリジン
KR20250149802A (ko) Akt1의 공유결합 변형제 및 이의 용도
US20250084056A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
AU2016304331A1 (en) Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent.
WO2020187292A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
JPWO1998042680A1 (ja) 新規なアニリド化合物及びこれを含有する医薬
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
JP2022521784A (ja) Ｉｒｅ１阻害のためのピラゾロピリジン化合物
TWI905898B (zh) 作為ｓｏｓ１抑制劑的新穎呔衍生化合物及其用途
US20250092032A1 (en) Deoxycytidine kinase inhibitors
KR20250097910A (ko) 포스파티딜이노시톨 3-키나제의 신규 억제제
US20160200706A1 (en) Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230531